H.R. 1223 · 115th Congress
OPEN Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BilirakisSponsor43 cosponsors · 16 D, 27 R
D
Butterfield
MM
R
McCaul
RF
R
Frelinghuysen
LL
R
Lance
DS
D
Soto
DD
R
Donovan
AE
D
Eshoo
TM
R
Murphy
MM
R
Mullin
DN
D
Norcross
JF
R
Fortenberry
JH
D
Huffman
DB
R
Bacon
DW
R
Webster
SP
R
Palazzo
FR
R
Rooney
ZL
D
Lofgren
CM
R
McMorris Rodgers
AS
D
Sires
ES
D
Swalwell
FU
R
Upton
PO
R
Olson
BL
R
Long
MB
R
Brooks
CS
D
Shea-Porter
SS
R
Stivers
WC
D
Clay
BC
R
Comstock
BF
R
Fitzpatrick
AH
D
Hastings
CS
R
Smith
ML
D
Lujan Grisham
DY
R
Young
JC
R
Culberson
KR
D
Rice
BW
D
Watson Coleman
PV
D
Visclosky
DR
R
Reichert
LM
R
Messer
BP
R
Posey
PR
R
Roskam
TP
R
Poe
DP
D
Price2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act
What it does: CRS summary · Introduced in House · Feb 27, 2017
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Department of Health and Human Services (HHS) to extend by six months the exclusivity period for a drug or biological product approved by the Food and Drug Administration (FDA) when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease).
HHS may revoke an extension if the application submitted to the FDA for the new indication contained an untrue material statement.
HHS must notify the public of products that receive this extension and patents related to those products.
Products may receive only one extension under this bill. Extensions under this bill are in addition to other extensions.
The bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition.Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: OPEN Act
Also known as: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017
Latest action (Mar 3, 2017): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Feb 27, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.